SymBio Pharmaceuticals Limited (TYO:4582)

Market Cap	7.61B -7.3%
Revenue (ttm)	1.31B -46.7%
Net Income	-4.78B
EPS	-95.12
Shares Out	63.99M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,242,900
Average Volume	7,588,985
Open	112.00
Previous Close	114.00
Day's Range	112.00 - 121.00
52-Week Range	81.00 - 229.00
Beta	0.46
RSI	50.04
Earnings Date	May 7, 2026

About SymBio Pharmaceuticals

SymBio Pharmaceuticals Limited engages in the and development, manufacturing and sales of pharmaceuticals and other related operations in Japan and internationally. It offers SyB V-1901, an antiviral drug for post-transplant infections, blood cancers and solid tumors, and neurodegenerative diseases; SyB L-1701, an RTD liquid formulation; SyB L-1702, an RI administration under the TREAKISYM name; and C-1101, an antiviral drug BCV injectable and oral formulations against double-stranded DNA viruses. The company was incorporated in 2005 and is bas...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2005
• Employees: 108
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4582

Financial Performance

In 2025, SymBio Pharmaceuticals's revenue was 1.31 billion, a decrease of -46.67% compared to the previous year's 2.45 billion. Losses were -4.78 billion, 24.6% more than in 2024.